The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Recent melanoma articles from OncologySTAT.com

This topic has 3 replies, 1 voice, and was last updated 13 years, 3 months ago by H555.

Post

May 24, 2012 at 2:40 am

Quote

Gene_S

Participant

News

SCREEN: Melanoma Deaths Reduced by Half in Largest Study Ever

Elsevier Global Medical News, 2012 May 18, B Jancin

In the Pipeline: BRAF-Plus-MEK Inhibition Slows Melanoma

Elsevier Global Medical News, 2012 May 17, P Wendling

Women 30% More Likely to Survive Melanoma Than Men

Elsevier Global Medical News, 2012 Apr 30, MA Moon

Cyclops Lambs Played Important Role in Vismodegib's Approval

Elsevier Global Medical News, 2012 Apr 4, D Mcnamara

Limb Perfusion for In-Transit Melanoma Reduces Distant Recurrences

Elsevier Global Medical News, 2012 Mar 30, N Osterweil

Melanoma on Scalp Signals Worse Prognosis Than Other Sites

Elsevier Global Medical News, 2012 Mar 29, N Osterweil

Extramammary Paget's Needs More Than Mohs

Elsevier Global Medical News, 2012 Mar 21, B Jancin

New Vemurafenib Data Highlights Long-Term Melanoma Survival

Elsevier Global Medical News, 2012 Feb 22, MA Moon

Expert Opinion

Treatment of Brain Metastases in Patients With Melanoma

Free Journal Content

Lancet Oncol, 2012 Mar 27, R Fisher, et al

Journal Scans: Research

Adjuvant Radiotherapy After Lymphadenectomy for Melanoma

Lancet Oncol, 2012 May 9, BH Burmeister, et al

Possible Link Between B-Cell Lymphoproliferative Disorders and Merkel Cell Carcinoma

Br J Haematol, 2012 May 1, T Tadmor, et al

Increased Risk of Non-melanoma Cancers With CDKN2A Mutations

J Natl Cancer Inst, 2012 Apr 24, B Mukherjee, et al

Association of Galectin-3 Expression With Melanoma Progression and Prognosis

Eur J Cancer, 2012 Apr 1, ER Brown, et al

Ipilimumab in Patients With Melanoma and Brain Metastases

Lancet Oncol, 2012 Mar 26, K Margolin, et al

Journal Scans: Review

Treatment Advances in Basal Cell Carcinoma: Hedgehog Inhibitors

Free Journal Content

Semin Oncol, 2012 Apr 1, R Kudchadkar, et al

Primary Malignant Melanoma of the Head and Neck

Oral Oncol, 2012 Jan 20, AK Vikey, et al

Emerging Molecular Classification System for Melanoma Treatment

Lancet Oncol, 2011 Sept 1, E Romano, et al

Videos

Personalized Medicine: A Long Way to Go

OncologySTAT Video Network

EJC News Focus, 2011 Nov 1,

Viewing 2 reply threads

Replies

- - May 24, 2012 at 3:18 am
  - Quote
  H555
  Participant
  thanks as a new Zelboraf patient i'm particuarly pleased with this one
  
  New Vemurafenib Data Highlights Long-Term Melanoma Survival
  
  thank you for diligently hunting these down and posting them.
- - May 24, 2012 at 3:18 am
  - Quote
  H555
  Participant
  thanks as a new Zelboraf patient i'm particuarly pleased with this one
  
  New Vemurafenib Data Highlights Long-Term Melanoma Survival
  
  thank you for diligently hunting these down and posting them.
- - May 24, 2012 at 3:18 am
  - Quote
  H555
  Participant
  thanks as a new Zelboraf patient i'm particuarly pleased with this one
  
  New Vemurafenib Data Highlights Long-Term Melanoma Survival
  
  thank you for diligently hunting these down and posting them.

Viewing 2 reply threads

Tagged: cutaneous melanoma

You must be logged in to reply to this topic.

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.